Julie Fierle

Julie Fierle has over 9 years of work experience in the scientific field. In 2021, they began working as a Scientist at NBE-Therapeutics AG. From 2015 to 2020, they were a Postdoctoral Researcher at the Ludwig Institute for Cancer Research, where they developed novel antibody-based therapeutic approaches to redirect T cell effector functions to target tutor cells. In 2014, they were a Masters Student at The Scripps Research Institute, where they conducted cell-based and biochemical assays for the analysis of ER signaling in breast cancer cell lines. In 2012, they were an Antibody Development Intern at Roche Diagnostics in Penzberg, Germany, where they developed and characterised antibodies for use in diagnostic assays. Finally, in 2012, they were a Bachelor Student at INSERM.

Julie Fierle has a solid educational background. Julie obtained a Bachelor of Science in Molecular Medicine from The University of Freiburg in 2012, followed by a Master of Science in Molecular Medicine from The University of Freiburg in 2015. Julie then went on to pursue a Doctor of Philosophy in Cancer and Immunology from the University of Lausanne - UNIL, which they completed in 2020.